Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Diagnostics Division highlights Strong growth despite a high base in HY 2021 CHFbn YoY CER growth Core Lab 1,2 Point of Care2 Molecular Lab² Diabetes Care Pathology Lab +10% 0.0 -5% 1.0 2.0 +1% +46% EMEA 3 Asia-Pacific North America Latin America 3.0 +4% • 4.0 · Immunodiagnostics (+6%) Clinical Chemistry (+8%) • Custom biotech (-12%) • POC Immunodiagnostics (+54%) • POC Molecular³ (+75%) • Virology (+4%) . • Blood glucose monitoring (-7%) • ⚫ Insulin delivery systems (+17%) • Advanced staining (+9%) • Companion diagnostics (+26%) CER-Constant Exchange Rates; POC-point of care; 1 Underlying growth of Core Lab excluding Roche Information Solutions: +4%; 2 Sales in Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales=90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q121 LS Alliances-21mCHF, Q2 21=23mCHF, Q3 21-23mCHF, Q4 21=20mCHF; 3 EMEA-Europe, Middle East and Africa Roche 37 57

View entire presentation